Learn More
Human recombinant interleukin-1 beta (IL-1beta), administered by intravenous drop infusion, at doses of 10-20 ng/kg daily over 5 days, to a group of 67 patients suffering from malignant tumors and(More)
The clinical study of human recombinant IL-1beta as a leukopoiesis protector, administered intravenously and subcutaneously, simultaneously with the chemotherapy, confirmed the "protective" effect of(More)
  • 1